title: Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy.
abstract: The focus was on salivary glands in cysteamine-induced duodenal ulcer and the different effects of antiulcer agents on cysteamine-induced duodenal ulcer in sialoadenectomized but not gastrectomized rats. We tested antiulcer agents on cysteamine-induced duodenal ulcer in rats (agents/kg i.p.) simultaneously with cysteamine 400 mg/kg s.c., rat killed 24 h thereafter subjected to no surgery (normal), to gastrectomy (24 h before) or sialoadenectomy, acute (24 h before) or chronic (21 days before). (i) Ulcerogenesis: cysteamine-induced duodenal ulcer had the same severity and incidence in normal, gastrectomized or acutely or chronically sialoadenectomized rats. (ii) Antiulcer effect under normal conditions or following gastrectomy: in normal or gastrectomized rats all agents tested, gastric pentadecapeptide BPC 157 [currently in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL-14736, Pliva) (10.0 microg or 10.0 ng), ranitidine (10 mg), atropine (10 mg), omeprazole (10 mg)] inhibited cysteamine-induced duodenal ulcers, acting through gastric acid-independent mechanisms. Following sialoadenectomy, acute or chronic: ranitidine, omeprazole and atropine were completely ineffective, while pentadecapeptide BPC 157 could protect. Thus, we found that contrary to stomach, salivary glands are implicated in cytoprotective agent activity (standard agents were ineffective after sialoadenectomy). Also, gastric pentadecapeptide BPC 157 was consistently associated with a cytoprotective effect, suggesting a beneficial activity distinctive from that of H2-receptor blockers, proton-pump inhibitors and anticholinergics; but probably replacing missing salivary glands factors.
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001285:Atropine / Q000627:therapeutic use; D003543:Cysteamine; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005743:Gastrectomy; D009853:Omeprazole / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D011506:Proteins / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013363:Submandibular Gland / Q000503:physiopathology* / Q000601:surgery
chemical_list: D000897:Anti-Ulcer Agents; D010446:Peptide Fragments; D011506:Proteins; D003543:Cysteamine; D001285:Atropine; D011899:Ranitidine; C083833:BPC 157; D009853:Omeprazole